Cogent Biosciences Inc’s recent filing unveils that its Director Fairmount Funds Management LLC acquired Company’s shares for reported $25.0 million on Jul 10 ’25. In the deal valued at $9.00 per share,2,777,777 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 9,003,418 shares worth roughly $301.97 million.
Then, Pinnow Cole bought 43,750 shares, generating $332,412 in total proceeds. Upon buying the shares at $7.60, the Chief Commercial Officer now owns 45,848 shares.
Wedbush upgraded its Cogent Biosciences Inc [COGT] rating to an Outperform from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who increased its forecast for the stock in early November from “a Hold” to “a Buy”. Stifel began covering COGT with “Hold” recommendation on October 16, 2025. Raymond James started covering the stock on September 03, 2025. It rated COGT as “a Strong buy”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock fall -0.86% to $33.54. Over the last five days, the stock has gained 126.32%. Cogent Biosciences Inc shares have risen nearly 223.12% since the year began. Nevertheless, the stocks have risen 330.00% over the past one year. While a 52-week high of $36.29 was reached on 11/13/25, a 52-week low of $3.72 was recorded on 04/09/25.
Levels Of Support And Resistance For COGT Stock
The 24-hour chart illustrates a support level at 31.70, which if violated will result in even more drops to 29.85. On the upside, there is a resistance level at 35.72. A further resistance level may holdings at 37.89.
How much short interest is there in Cogent Biosciences Inc?
A steep rise in short interest was recorded in Cogent Biosciences Inc stocks on 2025-10-31, dropping by -1.96 million shares to a total of 15.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 17.01 million shares. There was a decline of -13.01%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $17 price target.
